Nasal Drug Delivery Systems Market, by Dosage Form (Nasal Spray, Nasal Drops, Nasal Gels, Nasal Powders, and Others), by Container Type (Non-pressurized Containers and Pressurized Containers), by System Type (Multi Dose, Bi Dose, and Unit Dose), by Therapeutics Application (Allergic and Non-allergic Rhinitis, Nasal Congestion, Vaccination, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI1944

Pages :156

Formats :

Excel and PDF

Industry : Medical Devices

Market Challenges And Opportunities

Global Nasal Drug Delivery Systems Market: Restraint

Limitations associated with nasal drug delivery system such as histological toxicity or lesser area of absorption as compared to orally administered drug hinders the nasal drug delivery systems market growth.

Restraints & Challenges:

Limitations associated with nasal drug delivery systems

Increasing product launches by market players is expected to drive the global nasal drug delivery systems market growth.

Increasing product launches by market players is expected to drive the market growth over the forecast period. For instance, on December 22, 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.), announced the launch of generic version of Narcan1 (naloxone hydrochloride nasal spray). Moreover, naloxone hydrochloride nasal spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems or inability to respond.

Global Nasal Drug Delivery Systems Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a positive impact on the global nasal drug delivery systems market, owing to increased product launches by market players for protecting patients from coronavirus infection. For instance, on February 09, 2022, Glenmark Pharmaceuticals Limited, a global pharmaceutical company and Canada based pharmaceutical company SaNOtize Research & Development Corp., announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Increasing product approvals by regulatory authorities is expected to drive growth of the global nasal drug delivery systems market.

Increasing product approvals by regulatory authorities is expected to drive growth of the global nasal drug delivery systems market. For instance, on March 18, 2019, Aptar Pharma, a drug delivery systems provider, had announced that the company’s product Bidose nasal spray device had received approval from the U.S. Food and Drug administration (FDA) for a breakthrough therapy in the field of depression.